Trial reportEuropean journal of nutrition2023
Lactobacillus GG is associated with mucin genes expressions in type 2 diabetes mellitus: a randomized, placebo-controlled trial.
Trial report in European journal of nutrition, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05066152 (The Effects of Single Probiotic on Glycemic Control, Lipid Profile, Some of Inflammatory Cytokines and Gene Expression Levels in Type 2 Diabetic Patients), which is not on this map. Cited by 12 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Effects of Single Probiotic on Glycemic Control, Lipid Profile, Some of Inflammatory Cytokines and Gene Expression Levels in Type 2 Diabetic Patients
Who cites it
12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 23 citations in OpenAlex.
- Effects of Probiotic and Synbiotic Supplementation on Glycemic Indices in Adult Individuals with Prediabetes and Type 2 Diabetes Mellitus: A Grade-Assessed Systematic Review and Dose-Response Meta-analysis of RCTs.Probiotics and antimicrobial proteins · 2026Pooled it
- Glucose Parameters, Inflammation Markers, and Gut Microbiota Changes of Gut Microbiome-Targeted Therapies in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.The Journal of clinical endocrinology and metabolism · 2025Pooled it
- Effect of probiotics derivatives (postbiotics and metabiotics) on glycemic control in individuals with type 2 diabetes: a randomized clinical trial (DELI_Diab study).Frontiers in endocrinology · 2026Trial
- Studies on the Probiotic, Adhesion, and Induction Properties of Artisanal Lactic Acid Bacteria: to Customize a Gastrointestinal Niche to Trigger Anti-obesity Functions.Probiotics and antimicrobial proteins · 2025Article
- Review
- Network meta-analysis of randomized control trials evaluating the effectiveness of various probiotic formulations in patients with type 2 diabetes mellitus.Diabetology & metabolic syndrome · 2025Review
- Probiotics as Antioxidant Strategy for Managing Diabetes Mellitus and Its Complications.Antioxidants (Basel, Switzerland) · 2025Review
- An update and overview of the various health-related benefits of probiotics: A focus on clinical trials demonstrating efficacy, tolerability and use in patients with impaired glucose tolerance and type 2 diabetes.Diabetes, obesity & metabolism · 2025Review
- Limosilactobacillus reuteri ameliorates maternal separation stress in newborn mice and alters subsequent adult behaviour.Beneficial microbes · 2024Article
- Molecular Mechanisms ofMicroorganisms · 2024Review
- Gut microbiota and metabolite interface-mediated hepatic inflammation.Immunometabolism (Cobham, Surrey) · 2024Review
- Targeting metabolic pathways: a novel therapeutic direction for type 2 diabetes.Frontiers in cellular and infection microbiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
purposeRecent studies indicate that dysbiosis of gut microbiota and low-grade inflammation are important pathogenic determinants of type two diabetes mellitus (T2DM). The aim of this study is to investigate the effects of Lactobacillus GG on glycemic control, lipid profile, inflammatory parameters, and some gene expression levels in individuals with T2DM.
methodsIn a randomized, placebo-controlled trial, 34 women, aged 30-60 years with T2DM consumed daily probiotics or placebo for 8 weeks. The probiotic group consumed 10 × 10
resultsFasting blood glucose was significantly decreased in probiotic (p = 0.049) and placebo (p = 0.028), but there was no difference between the groups. In the probiotic group, no significant difference was observed in HbA1c, fructosamine, lipid profile, and inflammatory variables compared to baseline. In this group, with LGG supplementation, mucin 2 and 3A (MUC2 and MUC3A) gene expressions increased more than ninefolds (p = 0.046 and p = 0.008, respectively) at post-treatment. Meanwhile, there was no significant change in any of the gene expressions in the placebo group. There was no significant difference in energy, protein, dietary fiber, and cholesterol intakes between placebo and probiotic groups during the study. However, daily fat intake (p = 0.003), body weight (p = 0.014), and body fat (p = 0.015) in the probiotic group were significantly decreased.
conclusionIn this study, the effects of a single probiotic strain were investigated for 8 weeks. At the end of the study, although there was no finding that clearly reflected on the glycemic parameters of T2DM, its beneficial effects on the expression of mucin genes, which are responsible for weight loss and protection of intestinal barrier functions, cannot be denied. Further studies are needed to reveal the importance of these findings. CLINICAL
trial registrationID: NCT05066152, October 4, 2021 retrospectively registered in ClinicalTrials.gov PRS web site.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.